

## ***Review questions***

Review question 1: What is the comparative effectiveness of pharmacological interventions to treat daytime hypersomnolence associated with PD?

Review question 2: What is the effectiveness of physiotherapy (physical activity) compared with usual care?

Review question 3: What is the effectiveness of nutritional support compared with usual care?

Review question 4: What are the needs of people with Parkinson's disease for advance directives and palliative care plans throughout the course of their disease?

Review question 5: What is the effectiveness of speech and language therapy (SLT) compared with usual care?

Review question 6: What are the specific information needs of women of child-bearing age with Parkinson's disease

Review question 7: What is the effectiveness of occupational therapy (OT) compared with usual care on the complications of PD?

Review question 8: What factors should healthcare professionals consider as potential predictors for the development of impulse control behaviours as an adverse effect of dopaminergic treatment?

Review question 9: How should dopaminergic treatment be managed in people who have developed impulse control disorder as an adverse effect?

Review question 10: What are the information needs of people with Parkinson's disease and their families and carers about the potential for impulse control disorder (ICD) when considering or starting dopaminergic treatment?

Review question 11: What is the comparative effectiveness of pharmacological interventions to treat nocturnal akinesia associated with PD?

Review question 12: What is the comparative effectiveness of pharmacological interventions for orthostatic hypotension associated with PD?

Review question 13: What is the comparative effectiveness of pharmacological interventions for thermoregulatory dysfunction / hyperhidrosis associated with PD?

Review question 14: What is the comparative effectiveness of levodopa preparations, monoamine oxidase B inhibitors, dopamine agonists and anticholinergics as first-line treatment of motor symptoms?

Review question 15: In people for whom deep brain stimulation (DBS) and levodopa–carbidopa intestinal gel (LCIG) are treatment options, what is the comparative effectiveness of DBS, LCIG, and best medical treatment?

Review question 16: Is there a benefit in receiving deep brain stimulation (DBS) in earlier, stages of PD compared to usual care?

Review question 17: In people who are contraindicated for deep brain stimulation, what is the effectiveness of levodopa–carbidopa intestinal gel (LCIG) plus best medical therapy compared to best medical therapy alone?

Review question 18: In people who are contraindicated for levodopa–carbidopa intestinal gel (LCIG), what is the effectiveness of deep brain surgery plus best medical therapy, compared to best medical therapy alone?

Review question 19: What is the comparative effectiveness of pharmacological interventions as adjuvants to levodopa preparations?

Review question 20: What is the comparative effectiveness of donepezil, galantamine, memantine and rivastigmine for cognitive enhancement in dementia associated with Parkinson’s disease?

Review question 21: What is the comparative effectiveness of pharmacological interventions for psychotic symptoms associated with PD?

Review question 22: What is the comparative effectiveness of pharmacological interventions to treat REM sleep behaviour disorder (RBD) associated with PD?